Cellular Engineering Technologies (CET) is a biotechnology company in personalized and regenerative medicine. Our mission is to decrease the cost and failure rate of drug development and create therapeutic modalities in regenerative medicine. CET specializes in cell manufacturing and contract research services directed towards biopharmaceutical market segments that interface with stem cell technology. CET has over a decade of being in business with core competencies in specialized tissue culture media formulation and cell manufacturing along with research services that use human non-embryonic sources and non-controversial cells for bioprocessing. In addition, CET also manufactures a first-in-kind induced pluripotent stem cell (IPSC) technology that is virus-free and oncogene-free, which has the most predictability for drug discovery and safety for cell therapy and gene therapy. CET also has several decades of expertise in cellular and tissue engineering that we deploy to solve customer problems in drug development and personalized medicine. CET has distribution capabilities to service customers in Canada, United States, Asia and Europe.
Alan Moy, MD, Chief Executive Officer and Founder
Alan Moy, M.D., a physician-scientist, was previously on faculty for 13 years at the University of Iowa Department of Internal Medicine and Biomedical Engineering. Dr. Moy founded the company in 2000. Dr. Moy received a Bachelor's degree in Biochemistry from the University of California, Davis and an M.D. from Creighton University. He received postgraduate education in Internal Medicine from St. Louis University and completed a fellowship in Pulmonary Medicine and Critical Care Medicine at the University of Iowa. Dr. Moy's research expertise is in the area of vascular biology and tissue engineering. Dr. Moy is also listed in the 2010 Who's Who in America and is listed in 2011 as a Leading Physician of the World by the International Association of Healthcare Professions.